Kerr on Oncology

+ Add to Email Alerts
- New Research Points to a Better Biomarker for MSI mCRC
- Phase 1 Trials: Are We Using Optimal Drug Dose Schedules?
1
- AI in Oncology: Sorting Through Misinformation
- Health Professionals: Reducing the Risks for Nuclear War
1
- Recent UN Health Declarations: Clichés and Lies?
1
- Celebrating 75th Anniversary of the National Health Service
- Global Cancer Control: Working Together to Make a Difference
1
- More Expensive Alcohol Saves Lives. Will It Affect Cancer?
92
- Debulking Primary Disease: Does It Spur Micro-Metastases?
4
- Cycle of Cancer Immunity: A Primer for Oncologists
- FOxTROT Trial Sheds Light on Neoadjuvant Therapy for CRC
- Does Somatic Variation Affect ctDNA Testing?
- The End of England's Long-Term National Cancer Plan: Costing Lives?
1
- ESMO 2022 New Guidelines Provide 'Clear Blueprint' for Managing IO Toxicity
- Ukrainian Refugees With Cancer: Where Does the Burden Go?
- Doctors in Film: Which Movies Are Most Inspirational to You?
21
- Pharmacokinetically Guided Dosing: The Way Forward?
- Cancer Control in Sub-Saharan Africa: Investment Needed
3
- Using ctDNA to Guide Adjuvant Therapy in Stage II CRC
1
- Devolved Healthcare: The Benefits and Drawbacks
1